Viral loads (copies of RNA per ml of plasma) of HIV/AIDS patients, who volunteered for clinical trial of the Medicinal synthetic Aluminum-magnesium silicate, were assessed, before and after they were treated. The trea...Viral loads (copies of RNA per ml of plasma) of HIV/AIDS patients, who volunteered for clinical trial of the Medicinal synthetic Aluminum-magnesium silicate, were assessed, before and after they were treated. The treatment lasted 4 weeks, 8 weeks and 12 weeks respectively. A patient who could not access approved laboratory for viral load test on time, continued the treatment?for 24 weeks. Following treatment with the medicine, mean viral load of HIV/AIDS patients reduced (P < 0.05) from 18875.00 ± 17059.18 to 327.50 ± 226.84. Rates of the viral load reduction were: 86% after 4 weeks, 96% after 8 weeks and 99.71% after 12 weeks. Clinical signs complained of, by the patients during the treatment, included, fever, dermatitis, boils, joint pain, leg edema and sore throat. These clinical signs ceased when they were treated, so that the antiretroviral treatment was completed. The patient who was on the medication for 24 weeks had no adverse drug reaction.展开更多
<i>COVID</i>-19 <i>virus</i> has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first sta...<i>COVID</i>-19 <i>virus</i> has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first stage (attachment to cells) and mop its extra-cellular particles. Positively charged particles would similarly mop/destroy cells it infects because unlike healthy cells which are neutral, infected/tumor cells have negative electrical charges. <i>Nanoparticles</i> (0.96 nm) of Aluminum-magnesium silicate (AMS), WHO-approved medicine/adjuvant have both negative and positive charged ends. As adjuvant it improves antimicrobials’ efficacies (clearing secondary infections) while as silicate it enhances immunity. By inhibiting viral replication;mopping extra-cellular viruses/abnormal cells;clearing secondary infections;enhancing immunity, AMS terminates viral-infections/abnormal cells’ metastases. Natural AMS has impurities and its deposits are not found in Nigeria. So, Aluminum silicate and Magnesium silicate (WHO-approved medicines) were used for <i>Medicinal synthetic AMS</i> {MSAMS: Al<sub>4</sub> (SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub> (SiO<sub>4</sub>)<sub>3</sub>}. Since AMS is un-absorbable, dextrose monohydrate is incorporated in MSAMS-formulations to convey its <i>Nanoparticles</i> into blood for circulation to all organs/tissues (active-transportation). The MSAMS achieved quick cure (within 3 days) of all four COVID-19 patients used for its first-phase trial (one in Nigeria, two in Cameroon, one in Tanzania).展开更多
文摘Viral loads (copies of RNA per ml of plasma) of HIV/AIDS patients, who volunteered for clinical trial of the Medicinal synthetic Aluminum-magnesium silicate, were assessed, before and after they were treated. The treatment lasted 4 weeks, 8 weeks and 12 weeks respectively. A patient who could not access approved laboratory for viral load test on time, continued the treatment?for 24 weeks. Following treatment with the medicine, mean viral load of HIV/AIDS patients reduced (P < 0.05) from 18875.00 ± 17059.18 to 327.50 ± 226.84. Rates of the viral load reduction were: 86% after 4 weeks, 96% after 8 weeks and 99.71% after 12 weeks. Clinical signs complained of, by the patients during the treatment, included, fever, dermatitis, boils, joint pain, leg edema and sore throat. These clinical signs ceased when they were treated, so that the antiretroviral treatment was completed. The patient who was on the medication for 24 weeks had no adverse drug reaction.
文摘<i>COVID</i>-19 <i>virus</i> has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first stage (attachment to cells) and mop its extra-cellular particles. Positively charged particles would similarly mop/destroy cells it infects because unlike healthy cells which are neutral, infected/tumor cells have negative electrical charges. <i>Nanoparticles</i> (0.96 nm) of Aluminum-magnesium silicate (AMS), WHO-approved medicine/adjuvant have both negative and positive charged ends. As adjuvant it improves antimicrobials’ efficacies (clearing secondary infections) while as silicate it enhances immunity. By inhibiting viral replication;mopping extra-cellular viruses/abnormal cells;clearing secondary infections;enhancing immunity, AMS terminates viral-infections/abnormal cells’ metastases. Natural AMS has impurities and its deposits are not found in Nigeria. So, Aluminum silicate and Magnesium silicate (WHO-approved medicines) were used for <i>Medicinal synthetic AMS</i> {MSAMS: Al<sub>4</sub> (SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub> (SiO<sub>4</sub>)<sub>3</sub>}. Since AMS is un-absorbable, dextrose monohydrate is incorporated in MSAMS-formulations to convey its <i>Nanoparticles</i> into blood for circulation to all organs/tissues (active-transportation). The MSAMS achieved quick cure (within 3 days) of all four COVID-19 patients used for its first-phase trial (one in Nigeria, two in Cameroon, one in Tanzania).
